The US Food and Drug Administration received a supplemental New Drug Application for selinexor (XPOVIO) in combination with ruxolitinib for patients with myelofibrosis, according to Karyopharm Therapeutics, the drug’s manufacturer.
The submission is based on data from the phase 3 SENTRY trial, which evaluated the combination in JAK inhibitor-naive patients and demonstrated spleen volume reduction and an overall survival signal, according to a press release by Karyopharm.
In a video with SOHO Insider from the 2026 ASCO Annual Meeting, Dr. Mascarenhas, a professor of medicine at the Icahn School of Medicine at Mount Sinai, discusses results from the phase 3 SENTRY trial. The trial is a randomized, double-blind, placebo-controlled trial of 60 mg selinexor in combination with ruxolitinib versus placebo plus ruxolitinib in patients with JAK inhibitor-naïve myelofibrosis.
Leave feedback about this